biologic

Varizig

Varicella Zoster Immune Globulin (Human)

Loss of exclusivitySeptember 2026projected — 12-year biologic exclusivity estimate
CompanyKamada Ltd.See this company's full patent-cliff portfolio

Drug detail

Brand nameVarizig
Active ingredientVaricella Zoster Immune Globulin (Human)
Strength125IU
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalSeptember 2014
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Varizig patent cliff — loss of exclusivity September 2026 | CliffBio